State Key Laboratory of Experimental Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):261-8. doi: 10.1016/j.clml.2012.03.002. Epub 2012 Apr 17.
To study the potential role of Delta-like-1 (DLK1) in myelodysplastic syndromes (MDS), we carried out a series of experiments and found that DLK1 mRNA levels are dysregulated in patients with MDS or acute myelogenous leukemia (AML), and its overexpression leads to dysfunction of 32D and 3T3 cells. We conclude that DLK1 dysfunction may contribute to abnormal hematopoiesis of MDS and may be 1 of the antioncogenes. Delta-like-1 (DLK1) is frequently expressed at elevated levels in CD34(+) cells from patients with MDS. To investigate its role in the pathogenesis of MDS, we tested bone marrow samples from a panel of patients with MDS, AML, or myeloproliferative neoplasms, with real-time polymerase chain reaction (PCR). We show here that DLK1 mRNA levels are higher in MDS patients and lower in AML patients than in healthy individuals. Myeloid progenitor 32D cells overexpressing DLK1 display increased apoptosis, reduced differentiation, and decreased cell number expansion, which is also accompanied by changes in cell cycle progression. Immortalized fibroblastic 3T3 cells can grow into tumors in nude mice but the size of tumors are smaller from those overexpressing DLK1. These observations suggest that DLK1 dysfunction may contribute to the ineffective hematopoiesis of MDS.
为了研究 Delta-like-1 (DLK1) 在骨髓增生异常综合征 (MDS) 中的潜在作用,我们进行了一系列实验,发现 MDS 或急性髓细胞白血病 (AML) 患者的 DLK1 mRNA 水平失调,其过表达导致 32D 和 3T3 细胞功能障碍。我们得出结论,DLK1 功能障碍可能导致 MDS 异常造血,可能是 1 种抑癌基因。Delta-like-1 (DLK1) 在 MDS 患者的 CD34(+) 细胞中经常高水平表达。为了研究其在 MDS 发病机制中的作用,我们用实时聚合酶链反应 (PCR) 检测了一组 MDS、AML 或骨髓增生性肿瘤患者的骨髓样本。我们在这里表明,与健康个体相比,MDS 患者的 DLK1 mRNA 水平较高,AML 患者的 DLK1 mRNA 水平较低。过表达 DLK1 的髓系祖细胞 32D 显示凋亡增加、分化减少和细胞数量扩增减少,这也伴随着细胞周期进程的变化。永生化成纤维细胞 3T3 细胞可以在裸鼠中生长为肿瘤,但过表达 DLK1 的肿瘤体积较小。这些观察结果表明,DLK1 功能障碍可能导致 MDS 无效造血。